MACC1 is a potential prognostic biomarker for cancer immunotherapy in lung adenocarcinoma.

This article focuses on the role of metastasis-associated colon cancer 1 (MACC1) as a prognostic biomarker and therapeutic target in lung adenocarcinoma (LUAD) immunotherapy. The study demonstrates that MACC1 is overexpressed in LUAD and correlates with immune microenvironment alterations, including immune checkpoint expression and tumor-infiltrating immune cells, which influence immune evasion and tumor progression. A MACC1-related Risk Score (MRRS) was developed using transcriptomic and immune infiltration data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, showing superior accuracy in predicting patient prognosis and response to immune checkpoint blockade (ICB) therapy compared to conventional biomarkers. In vivo experiments further revealed that combining MACC1 silencing with PD-L1 inhibition significantly suppresses tumor growth, supporting MACC1-targeted immunotherapy as a promising strategy for enhancing LUAD treatment outcomes.